Popular Weight-Loss Drugs Found To Cut Heart Attack and Stroke Risk

A review of 11 cardiovascular outcome trials with more than 90,000 patients found GLP-1 receptor agonists cut major adverse cardiovascular events by about 13% versus placebo.

The benefit appeared in both people with type 2 diabetes and those without diabetes, suggesting protection beyond blood sugar control.

The drugs were not linked to a major rise in serious safety problems over long-term treatment.

The findings support a possible lasting heart-protective effect from GLP-1 drugs such as semaglutide, liraglutide, and dulaglutide.